NEW
YORK, May 21, 2024 /PRNewswire/ -- Temple Street
Biotech is proud to announce the initiation of a pioneering
therapeutic antibody targeting prion protein for the treatment of
Alzheimer's disease. This project is in collaboration with a highly
respected Clinical Research Organization (CRO).
In 1906, German psychiatrist Alois
Alzheimer first identified the disease that now bears his
name, noting the presence of protein clumps, or plaques, in a
dementia patient's brain. Over a century later, the scientific
community continues to explore the origins of these plaques and
their detrimental impact on memory. Alzheimer's disease (AD)
currently affects over 26 million people worldwide, presenting a
critical need for innovative treatments.
Recent scientific advancements have unveiled a surprising
connection between the normal form of prion protein, previously
associated with diseases like mad cow disease, and plaque formation
in Alzheimer's disease. "This discovery is steering us in new
directions for Alzheimer's research," said Joseph Hernandez, Founder and Chairman of Temple
Street Biotech.
Researchers have found that amyloid-beta (A-β) oligomers, small
toxic structures, bind to hippocampal nerve cells essential for
memory. The normal prion protein has been identified as a binding
partner for these oligomers, an unexpected revelation given its
known role in other neurodegenerative diseases. "This finding
suggests a new avenue for understanding and potentially treating
Alzheimer's," added Hernandez.
Temple Street Biotech's therapeutic antibody aims to interrupt
this binding process, potentially reducing plaque formation and its
associated memory damage. This innovative approach represents a
significant step forward in the fight against Alzheimer's disease,
offering hope to millions of patients and their families.
For further information, please contact:
media@templestreetbiotech.com
About Temple Street Biotech:
Temple Street Biotech is at the forefront of innovative
biotechnology research, dedicated to developing breakthrough
treatments for neurodegenerative diseases. With a focus on
cutting-edge science and collaborative partnerships, Temple Street
Biotech aims to transform the landscape of therapeutic options for
patients worldwide.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/temple-street-biotech-initiates-groundbreaking-therapeutic-antibody-for-alzheimers-disease-302151894.html
SOURCE Temple Street Biotech, Inc.